ARCHIVE SEARCH
      -OR-  
 
  NEWS CHANNELS
Fitness News
Asthma Allergy News
 > Diabetes News
Women's Health News
Men's Health News

  MY NEWS
Personal Archive
My Account

  ABOUT THIS NEWSFEED
About Us
Advertise With Us
Feed Your Site
Contact Us


Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

 
Metformin May Increase Risk of Cognitive Impairment
Calcium supplementation may ameliorate this risk

FRIDAY, Sept. 20 (HealthDay News) -- Metformin may increase the risk of cognitive impairment in patients with diabetes; however, calcium supplementation may attenuate this risk, according to research published online Sept. 5 in Diabetes Care.

Eileen M. Moore, Ph.D., of the University of Melbourne in Australia, and colleagues conducted a subgroup analysis involving 104 patients with type 2 diabetes and 22 patients with impaired glucose tolerance who participated in the Australian Imaging, Biomarkers and Lifestyle study of aging. The authors sought to determine whether metformin, serum vitamin B12, or calcium supplements are associated with cognitive impairment in patients with diabetes.

The researchers found that, overall, patients with diabetes were 51 percent more likely to exhibit cognitive impairment than those without diabetes, and those taking metformin were more than twice as likely (2.23-fold) to exhibit cognitive impairment. After adjusting for age, sex, level of education, history of depression, serum vitamin B12, and metformin use, cognitive performance was improved for those patients who were also taking calcium supplements.

"Adequately powered, prospective, controlled trials are warranted to investigate further the association between diabetes, cognitive decline, and the effect of metformin therapy, as well as the possible amelioration using vitamin B12 and/or calcium supplementation," the authors write.

Several authors disclosed financial ties the biotechnology industry.

Abstract
Full Text (subscription or payment may be required)



Copyright © 2013 HealthDay. All rights reserved.


Back to Top Stories
  GOOGLE ADS